• KORU Medical Systems presented real-world study results at the Oncology Nursing Society Congress held May 13-17 on the use of its FreedomEDGE syringe infusion system in US community infusion clinics.
• The analysis found subcutaneous monoclonal antibody dosing was delivered reliably within expected clinical practice, supporting consistent administration in routine care.
• Nurses reported less ergonomic strain and greater ability to manage other tasks during infusions, pointing to potential staffing and throughput benefits for infusion centers.
• Patient and nurse feedback indicated strong satisfaction with the administration experience, reinforcing the device’s positioning in clinic-based subcutaneous delivery.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KORU Medical Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605181605BIZWIRE_USPR_____20260518_BW943304) on May 18, 2026, and is solely responsible for the information contained therein.